{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:25:53Z","timestamp":1787772353322,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The 1\u00b73\u00b75 project for disciplines of excellence\u2013Clinical Research Incubation Project, West China Hospital, Sichuan University","award":["2024HXFH031"],"award-info":[{"award-number":["2024HXFH031"]}]},{"name":"The 1\u00b73\u00b75 project for disciplines of excellence\u2013Clinical Research Incubation Project, West China Hospital, Sichuan University","award":["2021HXFH019"],"award-info":[{"award-number":["2021HXFH019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04990-x","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:34:53Z","timestamp":1781235293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Utidelone in patients with advanced soft tissue sarcoma refractory to anthracycline and antiangiogenic therapy (UTISARC): a single-arm phase II study"],"prefix":"10.1186","volume":"24","author":[{"given":"Jie","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Feng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Tiao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"7","key":"4990_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMra041866","volume":"353","author":"MA Clark","year":"2005","unstructured":"Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353(7):701\u201311.","journal-title":"N Engl J Med"},{"issue":"5","key":"4990_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11912-024-01630-6","volume":"27","author":"P Remiszewski","year":"2025","unstructured":"Remiszewski P, Filipek K, Pisklak A, Chmiel P, Rutkowski P, Czarnecka AM. Neoadjuvant or Adjuvant Chemotherapy in Soft-Tissue Sarcoma? Curr Oncol Rep. 2025;27(5):491\u2013515.","journal-title":"Curr Oncol Rep"},{"key":"4990_CR3","doi-asserted-by":"publisher","first-page":"1199292","DOI":"10.3389\/fphar.2023.1199292","volume":"14","author":"Z Tian","year":"2023","unstructured":"Tian Z, Yao W. Chemotherapeutic drugs for soft tissue sarcomas: a review. Front Pharmacol. 2023;14:1199292.","journal-title":"Front Pharmacol"},{"issue":"4","key":"4990_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson I, Verweij J, Gelderblom H, Hartmann JT, Sch\u00f6ffski P, Blay JY, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415\u201323.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4990_CR5","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/S1470-2045(22)00380-1","volume":"23","author":"P Pautier","year":"2022","unstructured":"Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, et al. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022;23(8):1044\u201354.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4990_CR6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1056\/NEJMoa2403394","volume":"391","author":"P Pautier","year":"2024","unstructured":"Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, et al. Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. N Engl J Med. 2024;391(9):789\u201399.","journal-title":"N Engl J Med"},{"issue":"11","key":"4990_CR7","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1001\/jamaoncol.2020.3689","volume":"6","author":"SM Pollack","year":"2020","unstructured":"Pollack SM, Redman MW, Baker KK, Wagner MJ, Schroeder BA, Loggers ET, et al. Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1\/2 Nonrandomized Clinical Trial. JAMA Oncol. 2020;6(11):1778\u201382.","journal-title":"JAMA Oncol"},{"issue":"9829","key":"4990_CR8","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879\u201386.","journal-title":"Lancet"},{"issue":"12","key":"4990_CR9","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","volume":"17","author":"O Mir","year":"2016","unstructured":"Mir O, Brodowicz T, Italiano A, Wallet J, Blay JY, Bertucci F, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1732\u201342.","journal-title":"Lancet Oncol"},{"issue":"21","key":"4990_CR10","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","volume":"24","author":"Y Chi","year":"2018","unstructured":"Chi Y, Fang Z, Hong X, Yao Y, Sun P, Wang G, et al. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. Clin Cancer Res. 2018;24(21):5233\u20138.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"4990_CR11","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1056\/NEJMoa1007056","volume":"363","author":"JE Butrynski","year":"2010","unstructured":"Butrynski JE, D\u2019Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363(18):1727\u201333.","journal-title":"N Engl J Med"},{"issue":"8","key":"4990_CR12","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"4990_CR13","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder M, Sch\u00f6ffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020;21(11):1423\u201332.","journal-title":"Lancet Oncol"},{"key":"4990_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejca.2021.04.034","volume":"152","author":"M Saerens","year":"2021","unstructured":"Saerens M, Brusselaers N, Rottey S, Decruyenaere A, Creytens D, Lapeire L. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. Eur J Cancer. 2021;152:165\u201382.","journal-title":"Eur J Cancer"},{"key":"4990_CR15","doi-asserted-by":"publisher","first-page":"114070","DOI":"10.1016\/j.intimp.2025.114070","volume":"148","author":"Y Cao","year":"2025","unstructured":"Cao Y, Wang W, Xu H, Yi H, Gao Y, Wan M, et al. Efficacy of immune checkpoint inhibitors in the treatment of soft tissue sarcoma: A systematic review and meta-analysis of clinical trials. Int Immunopharmacol. 2025;148:114070.","journal-title":"Int Immunopharmacol"},{"issue":"10028","key":"4990_CR16","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Sch\u00f6ffski","year":"2016","unstructured":"Sch\u00f6ffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629\u201337.","journal-title":"Lancet"},{"issue":"8","key":"4990_CR17","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016;34(8):786\u201393.","journal-title":"J Clin Oncol"},{"issue":"19","key":"4990_CR18","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","volume":"25","author":"RG Maki","year":"2007","unstructured":"Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755\u201363.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4990_CR19","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","volume":"18","author":"B Seddon","year":"2017","unstructured":"Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397\u2013410.","journal-title":"Lancet Oncol"},{"issue":"32","key":"4990_CR20","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","volume":"26","author":"N Penel","year":"2008","unstructured":"Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269\u201374.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4990_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12916-017-0831-7","volume":"15","author":"M Savina","year":"2017","unstructured":"Savina M, Le Cesne A, Blay JY, Ray-Coquard I, Mir O, Toulmonde M, et al. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Med. 2017;15(1):78.","journal-title":"BMC Med"},{"issue":"Suppl 5","key":"4990_CR22","doi-asserted-by":"publisher","first-page":"v9","DOI":"10.1093\/annonc\/mdm173","volume":"18","author":"P Fumoleau","year":"2007","unstructured":"Fumoleau P, Coudert B, Isambert N, Ferrant E. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;18(Suppl 5):v9\u201315.","journal-title":"Ann Oncol"},{"key":"4990_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.canlet.2019.04.029","volume":"456","author":"E Gazzano","year":"2019","unstructured":"Gazzano E, Buondonno I, Marengo A, Rolando B, Chegaev K, Kopecka J, et al. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive\/doxorubicin-resistant osteosarcoma cells and xenografts. Cancer Lett. 2019;456:29\u201339.","journal-title":"Cancer Lett"},{"issue":"3","key":"4990_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/bph.13395","volume":"173","author":"S Ye","year":"2016","unstructured":"Ye S, Zhang J, Shen J, Gao Y, Li Y, Choy E, et al. NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. Br J Pharmacol. 2016;173(3):613\u201326.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"4990_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00280-011-1571-6","volume":"68","author":"P Zhang","year":"2011","unstructured":"Zhang P, Sun M, Qiu R, Tang L, Dou G, Xu B. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;68(4):971\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4990_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-016-0297-7","volume":"9","author":"P Zhang","year":"2016","unstructured":"Zhang P, Tong Z, Tian F, Wang Y, Yang J, Li W, et al. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients. J Hematol Oncol. 2016;9(1):68.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"4990_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41419-021-03619-6","volume":"12","author":"F Li","year":"2021","unstructured":"Li F, Huang T, Tang Y, Li Q, Wang J, Cheng X, et al. Utidelone inhibits growth of colorectal cancer cells through ROS\/JNK signaling pathway. Cell Death Dis. 2021;12(4):338.","journal-title":"Cell Death Dis"},{"issue":"6","key":"4990_CR28","doi-asserted-by":"publisher","first-page":"112509","DOI":"10.1016\/j.isci.2025.112509","volume":"28","author":"J Zhou","year":"2025","unstructured":"Zhou J, Zhang K, Liu C, Long J, Gu H, Dong H, et al. Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. iScience. 2025;28(6):112509.","journal-title":"iScience"},{"issue":"3","key":"4990_CR29","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(17)30088-8","volume":"18","author":"P Zhang","year":"2017","unstructured":"Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncol. 2017;18(3):371\u201383.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4990_CR30","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.annonc.2020.10.600","volume":"32","author":"B Xu","year":"2021","unstructured":"Xu B, Sun T, Zhang Q, Zhang P, Yuan Z, Jiang Z, et al. Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial. Ann Oncol. 2021;32(2):218\u201328.","journal-title":"Ann Oncol"},{"issue":"8","key":"4990_CR31","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jamaoncol.2025.1694","volume":"11","author":"M Yan","year":"2025","unstructured":"Yan M, Lv H, Liu X, Wang S, Geng C, Song Y, et al. Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025;11(8):883\u20139.","journal-title":"JAMA Oncol"},{"key":"4990_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2019.12.001","volume":"126","author":"N Penel","year":"2020","unstructured":"Penel N, Mir O, Wallet J, Ray-Coquard I, Le Cesne A, Italiano A, et al. A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. Eur J Cancer. 2020;126:45\u201355.","journal-title":"Eur J Cancer"},{"issue":"25","key":"4990_CR33","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1200\/JCO.2015.60.8505","volume":"33","author":"IL Ray-Coquard","year":"2015","unstructured":"Ray-Coquard IL, Domont J, Tresch-Bruneel E, Bompas E, Cassier PA, Mir O, et al. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. J Clin Oncol. 2015;33(25):2797\u2013802.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4990_CR34","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1200\/JCO.2000.18.10.2081","volume":"18","author":"J Verweij","year":"2000","unstructured":"Verweij J, Lee SM, Ruka W, Buesa J, Coleman R, van Hoessel R, et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol. 2000;18(10):2081\u20136.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4990_CR35","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/1097-0142(19951201)76:11<2248::AID-CNCR2820761111>3.0.CO;2-Y","volume":"76","author":"SP Balcerzak","year":"1995","unstructured":"Balcerzak SP, Benedetti J, Weiss GR, Natale RB. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer. 1995;76(11):2248\u201352.","journal-title":"Cancer"},{"issue":"9","key":"4990_CR36","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1023\/A:1012272007146","volume":"12","author":"WJ K\u00f6stler","year":"2001","unstructured":"K\u00f6stler WJ, Brodowicz T, Attems Y, Hejna M, Tomek S, Amann G, et al. Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol. 2001;12(9):1281\u20138.","journal-title":"Ann Oncol"},{"issue":"6","key":"4990_CR37","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/cncr.33216","volume":"127","author":"N Somaiah","year":"2021","unstructured":"Somaiah N, Van Tine BA, Wahlquist AE, Milhem MM, Hill EG, Garrett-Mayer E, et al. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021;127(6):894\u2013904.","journal-title":"Cancer"},{"issue":"2","key":"4990_CR38","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1158\/1078-0432.CCR-09-1906","volume":"16","author":"S Jacobs","year":"2010","unstructured":"Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, et al. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children\u2019s oncology group. Clin Cancer Res. 2010;16(2):750\u20134.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4990_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ygyno.2014.07.101","volume":"135","author":"LR Duska","year":"2014","unstructured":"Duska LR, Blessing JA, Rotmensch J, Mannel RS, Hanjani P, Rose PG, et al. A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology\/Gynecologic Oncology Group Study. Gynecol Oncol. 2014;135(1):44\u20138.","journal-title":"Gynecol Oncol"},{"issue":"13","key":"4990_CR40","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2005.00.372","volume":"23","author":"S Okuno","year":"2005","unstructured":"Okuno S, Maples WJ, Mahoney MR, Fitch T, Stewart J, Fracasso PM, et al. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. J Clin Oncol. 2005;23(13):3069\u201373.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4990_CR41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/14796694.2025.2463798","volume":"21","author":"GM Cote","year":"2025","unstructured":"Cote GM, Chawla SP, Demetri G, Kasper B, Jones RL, Broto JM, et al. SaLudo: a randomized phase IIb\/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma. Future Oncol. 2025;21(8):943\u201351.","journal-title":"Future Oncol"},{"issue":"4","key":"4990_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s12032-025-02651-2","volume":"42","author":"P Remiszewski","year":"2025","unstructured":"Remiszewski P, Gaik W, Skora A, W\u0105\u017c J, Filipek K, Pisklak A, et al. Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice. Med Oncol. 2025;42(4):94.","journal-title":"Med Oncol"},{"issue":"22","key":"4990_CR43","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1200\/JCO.21.01829","volume":"40","author":"MM Gounder","year":"2022","unstructured":"Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, et al. Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022;40(22):2479\u201390.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4990_CR44","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41467-026-68729-1","volume":"17","author":"J Martin-Broto","year":"2026","unstructured":"Martin-Broto J, Casado A, Marquina G, Redondo A, Martinez-Trufero J, Valverde C, et al. Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study. Nat Commun. 2026;17(1):1873.","journal-title":"Nat Commun"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04990-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04990-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04990-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:37:43Z","timestamp":1787099863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04990-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4990"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04990-x","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee on Biomedical Research, West China Hospital of Sichuan University (reference number: 2022\u2009\u2212\u2009642). All participants provided written informed consent prior to enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JL and YTD have received speaker honoraria from Eisai, MSD, Novartis, Shanghai Junshi Biosciences, Chengdu Biostar Pharmaceuticals Co., Ltd. and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. YJ has received speaker honoraria from Roche, Eisai, MSD, Novartis, Shanghai Junshi Biosciences, Chengdu Biostar Pharmaceuticals Co., Ltd. and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"451"}}